NuCana CMO cancels 36.5M stock options

NuCana plc’s Chief Medical Officer Jeffrey D. Bloss agreed to cancel a portion of his stock options.

Rhea-AI Filing Summary

NuCana plc’s Chief Medical Officer Jeffrey D. Bloss agreed to cancel a portion of his stock options. He disposed of 36,539,720 options to the company as a disposition to issuer, without receiving any cash or other consideration.

The canceled options were part of a grant of 146,158,880 options with an exercise price of 0.0004 Pounds Sterling per share. Following the cancellation, 109,619,160 options tied to ordinary shares remain outstanding for Bloss and are scheduled to vest in three equal annual installments and expire on June 20, 2035, subject to his continued service.

Insider Trade Summary

Disposition: 36,539,720 shares

Disposition 1 txn

Insider Bloss Jeffrey D.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Disposition	Options	36,539,720	$0.00	$0.00

Holdings After Transaction: Options — 109,619,160 contracts (Direct)

Footnotes (4)

1. F1. D - Partial cancelation of vested options.
2. F2. The ordinary shares, nominal value 0.000004 Pounds Sterling per share (the "Ordinary Shares"), of NuCana plc (the "Company") underlying these options being canceled were part of a grant of 146,158,880 options that vested as to 25% on June 20, 2026, and had an exercise price of 0.0004 Pounds Sterling per share, with the remaining 109,619,160 to vest in three equal annual installments thereafter, subject to the Reporting Persons's continued service with the Company through the applicable vesting date.
3. F3. The remaining options will expire on June 20, 2035.
4. F4. The option was canceled by mutual agreement of the Reporting Person and the Company. The Reporting Person did not receive consideration for the cancellation.

Key Figures

Options canceled: 36,539,720 options Options remaining: 109,619,160 options Original option grant: 146,158,880 options +3 more

6 metrics

Options canceled 36,539,720 options Disposition to issuer on June 19, 2026

Options remaining 109,619,160 options Total options following transaction

Original option grant 146,158,880 options Grant underlying this transaction

Exercise price 0.0004 Pounds Sterling/share Exercise price of the original grant

Option expiration June 20, 2035 Expiration date of remaining options

Initial vesting 25% of grant Portion that vested on June 20, 2026

Key Terms

Disposition to issuer, vested options, exercise price, Ordinary Shares, +1 more

5 terms

Disposition to issuer financial

"transaction_action is described as an issuer disposition"

vested options financial

"Partial cancelation of vested options is noted in a footnote"

exercise price financial

"the options had an exercise price of 0.0004 Pounds Sterling per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Ordinary Shares financial

"the options are underlying ordinary shares of NuCana plc"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vesting financial

"the remaining options will vest in three equal annual installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NuCana (NCNA) report for Jeffrey D. Bloss?

NuCana reported that Chief Medical Officer Jeffrey D. Bloss canceled 36,539,720 stock options in a disposition to the company. This partial cancellation was by mutual agreement, and he did not receive any cash or other consideration in return.

How many NuCana (NCNA) options does Jeffrey D. Bloss hold after this transaction?

After the partial cancellation, Jeffrey D. Bloss holds 109,619,160 remaining stock options. These options are scheduled to vest in three equal annual installments and provide future potential equity exposure, subject to his continued service with NuCana.

What were the terms of the canceled NuCana (NCNA) options for Jeffrey D. Bloss?

The canceled options were part of a 146,158,880-option grant with an exercise price of 0.0004 Pounds Sterling per ordinary share. Twenty-five percent vested on June 20, 2026, and this vested tranche of 36,539,720 options was canceled by mutual agreement.

Did Jeffrey D. Bloss receive any payment for canceling NuCana (NCNA) options?

No, Jeffrey D. Bloss did not receive any consideration for canceling his vested options. The options were canceled by mutual agreement between him and NuCana, meaning this was a non-cash transaction that adjusted his outstanding equity compensation.

When do Jeffrey D. Bloss’s remaining NuCana (NCNA) options expire?

The remaining options held by Jeffrey D. Bloss will expire on June 20, 2035. These options are scheduled to vest in three equal annual installments, contingent on his continued service with NuCana through each relevant vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 06:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bloss Jeffrey D.

(Last) (First) (Middle)

C/O NUCANA PLC

3 LOCHSIDE WAY

(Street)

EDINBURGH UNITED KINGDOM EH12 9DT

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
NuCana plc [ NCNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	06/19/2026		D(1)			36,539,720	(2)	(3)	Ordinary Shares	36,539,720	$0.00(4)	109,619,160	D

Explanation of Responses:

1. D - Partial cancelation of vested options.

2. The ordinary shares, nominal value 0.000004 Pounds Sterling per share (the "Ordinary Shares"), of NuCana plc (the "Company") underlying these options being canceled were part of a grant of 146,158,880 options that vested as to 25% on June 20, 2026, and had an exercise price of 0.0004 Pounds Sterling per share, with the remaining 109,619,160 to vest in three equal annual installments thereafter, subject to the Reporting Persons's continued service with the Company through the applicable vesting date.

3. The remaining options will expire on June 20, 2035.

4. The option was canceled by mutual agreement of the Reporting Person and the Company. The Reporting Person did not receive consideration for the cancellation.

	/s/ Ian Webster, Attorney-in-Fact for Jeffrey D. Bloss	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)